Financials in USD. Standardized financial statements.
A compact view of how HAVN Life Sciences Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Revenue? | $276,473 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $186,780 | $4.60M | $0 |
| Gross Profit? | $89,693 | -$4.60M | $0 |
| Gross Margin? | +32.4% | 0.0% | 0.0% |
| Operating Expenses? | $9.90M | $24.35M | $41,124 |
| Operating Income? | -$9.81M | -$30.35M | -$40,576 |
| EBITDA? | -$7.50M | -$14.85M | $0 |
| Income Before Tax | -$22.44M | -$30.38M | -$40,576 |
| Income Tax Expense | $0 | $0 | -$206,297 |
| Net Income? | -$22.44M | -$30.38M | -$40,576 |
| EPS? | $-5.25 | $-8.47 | $-0.02 |
| Diluted EPS? | $-5.25 | $-8.47 | $-0.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality